NCT07150624 The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
| NCT ID | NCT07150624 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Anhui Provincial Hospital |
| Condition | Hepatocellular Carcinoma (HCC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 96 participants |
| Start Date | 2025-11-10 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 96 participants in total. It began in 2025-11-10 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A multicenter, open-label, randomized, controlled study. It is proposed to evaluate the treatment plan of receiving 930mg polyene phosphatidylcholine injection one day before the operation, twice a day, and 930mg polyene phosphatidylcholine injection twice a day,combined with 100mg of magnesium isoglycyrrhizinate injection once a day,from the 1st to the 5th day after the operation. Compared with the monotherapy regimen of no liver protection treatment before the operation and receiving magnesium isoglycyrrhizinate injection 100mg once a day from the 1st to the 5th day after the operation.The efficacy and safety of treating postoperative liver function injury in patients undergoing laparoscopic hepatectomy for hepatocellular carcinoma were compared.
Eligibility Criteria
Inclusion Criteria: 1. Diagnosed as HCC through imaging and laboratory tests, and capable of undergoing laparoscopic anatomical resection. 2. Surgical scope (defined by randomization stratification):Stratum 1: Major hepatectomy, involving the resection of at least 3 Couinaud liver segments, including right hemihepatectomy and extended right hemihepatectomy, etc.Stratum 2: Minor hepatectomy, involving the resection of no more than 2 Couinaud liver segments. This includes right posterior sectorectomy, right anterior sectorectomy, left lateral sectionectomy, single segmentectomy, etc. 3. During the operation, the Pringle method is used to block the first hepatic portal. Each block lasts ≤ 15 minutes, and the blocking procedure is performed 2 to 4 times. 4. Age: 18 - 80 years old. Gender: Open to both male and female. Body Mass Index (BMI): 18.5 - 28 kg/m². 5. Child-Pugh grade A or B, with a score of ≤ 7; ASA grades I to III. 6. Preoperative ICG R15 \< 10%, and the residual liver volume/standard liver volume \> 40%. 7. A single HCC (hepatocellular carcinoma), with a tumor diameter of less than 10 cm, without distant metastasis or invasion of the portal vein system. 8. Preoperative ALT \< 2x ULN (upper limit of normal). 9. No history of portal vein embolization prior to enrollment. If TACE treatment was previously received, it must have been completed \> 6 months ago; if systemic anti-tumor drug therapy was previously received, it must have been completed \> 4 weeks ago. 10. No liver-damaging treatment drugs were used within two weeks prior to enrollment. Exclusion Criteria: 1. Reserve liver vascular damage, including: reconstruction after severance, ligation, embolization, thrombosis, etc 2. Combined with abnormal coagulation function (prothrombin time prolonged by more than 3 seconds) 3. Combining obstructive jaundice, severe heart disease, severe kidney disease and other serious illnesses 4. During the operation, microwave treatment or a combination of microwave treatment was adopted 5. More than 4 times of blocking at the first hepatic hilum, or a single blocking duration longer than 15 minutes 6. Non-anatomic liver resection, where the remaining liver contains large areas of ischemic/edematous regions 7. More than 1000ml of blood transfusion during the operation 8. During the operation, an extra-hepatic disease was discovered. Other organs except the gallbladder needed to be removed simultaneously 9. During the operation, other intrahepatic lesions were discovered, which required combination with other surgeries, such as ablation or choledochojejunostomy 10. Diseases that have previously received systemic treatment with glucocorticoids, such as chronic kidney disease, inflammatory diseases, or other immune system-related disorders 11. Psychosis, severe neurosis, those who cannot cooperate with this experiment 12. Participated in other clinical trials within the previous 3 months before enrollment 13. Allergy or intolerance to benzoic acid, or to the study drug 14. Pregnant and lactating women 15. The researchers believe that any participants who have any other factors that would make them unsuitable for this trial should not be included
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07150624 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Hepatocellular Carcinoma (HCC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07150624 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07150624 currently recruiting?
Yes, NCT07150624 is actively recruiting participants. Contact the research team at liulx@ustc.edu.cn for enrollment information.
Where is the NCT07150624 trial being conducted?
This trial is being conducted at Hefei, China.
Who is sponsoring the NCT07150624 clinical trial?
NCT07150624 is sponsored by Anhui Provincial Hospital. The trial plans to enroll 96 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.